...
首页> 外文期刊>Arquivos de Gastroenterologia >Situa??o vacinal de pacientes com doen?a inflamatória intestinal
【24h】

Situa??o vacinal de pacientes com doen?a inflamatória intestinal

机译:炎症性肠道患者的情况

获取原文

摘要

BACKGROUND: Treatment for inflammatory bowel disease (IBD) includes a variety of immunosuppressants and biological agents, which increase the risk of infections due to altered cellular and humoral immunity. Prevention of these infections can be done through vaccination, however, patients with IBD are usually under-immunized. OBJECTIVE: Analyze the immunization status of patients with IBD and confront it with the current recommendations to verify if the immunization guidelines are being followed correctly. METHODS: Analytical cross-sectional study including 239 IBD patients being regularly followed in the Gastroenterology Service from Hospital de Clínicas da Universidade Federal do Paraná , which were subjected to a survey about their relevant demographic data and immunization status. RESULTS: The amount of patients that declared being unaware of their immunization status is high - between 34.3% (Tdap) and 52% (meningococcal) - excepting IIV, hepatitis B and HPV. The vaccines with the largest rates of patients declaring to have taken it are inactivated influenza vaccine (72.4%), BCG (55.3%), hepatitis B (48.3%), measles, mumps and rubella vaccine (43.8%) and DTaP (43%). The vaccines with the lowest rates of patients declaring to have taken it are Haemophilus influenza type b (0.8%), herpes zoster (2.1%) and HPV (3.4%). Patients that are being treated or have been treated with biological therapy have the largest immunization coverage for inactivated influenza vaccine (81%) and PPSV23 (25.9%), also they have the largest awareness rates for those vaccines. CONCLUSION: Although being a specialized service linked to a university hospital, vaccination coverage and patients’ awareness rates proved to be below the desirable level. Vaccination and recovery of the immunization history is recommended immediately after the diagnosis of IBD, regardless of the use of biological agents. Those findings support the need of implementing hospital guidelines and constantly verifying its application by the multidisciplinary team in specialized services in IBD.
机译:背景:炎症性肠病(IBD)的治疗包括各种免疫抑制剂和生物药物,这增加了由于细胞和体液免疫改变而导致感染的风险。预防这些感染可以通过疫苗接种来完成,然而,IBD患者通常是免疫的。目的:分析IBD患者的免疫状态,并与目前的建议对抗,以验证免疫指引是否正确。方法:分析横截面研究,包括239名IBD患者,患者在House deClínicasDa·达·德·普雷纳(Fartogersidade Federal DoParaná)胃肠学服务中携带,这是关于其相关人口统计数据和免疫状况的调查。结果:宣布不知道其免疫状态的患者的数量高 - 34.3%(TDAP)和52%(脑膜炎球菌) - 除外异常,乙型肝炎和HPV。具有最大的患者患者宣誓疫苗的疫苗是灭活的流感疫苗(72.4%),BCG(55.3%),乙型肝炎(48.3%),麻疹,腮腺炎和风疹疫苗(43.8%)和DTAP(43%) )。具有最低患者宣布患者的疫苗是嗜血杆菌流感B(0.8%),疱疹(2.1%)和HPV(3.4%)。治疗或已被生物疗法治疗的患者对灭活流感疫苗(81%)和PPSV23(25.9%)具有最大的免疫覆盖率,但它们对这些疫苗具有最大的认识率。结论:虽然是与大学医院相关的专业服务,但疫苗接种覆盖率和患者的意识率被证明低于所需水平。在诊断IBD后立即推荐免疫历史的疫苗接种和恢复,无论使用生物制剂。这些调查结果支持在IBD中专门服务中的多学科团队不断验证其在IBD专业服务中的申请。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号